If it sometimes seems like the idea of antibiotic resistance, though unsettling, is more theoretical than real, please read on.
Trump's HHS Nominee Got A Sweetheart Deal From A Foreign Biotech Firm | Kaiser Health News
When tiny Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it didn't issue stock on the open market. Instead, it offered a sweetheart deal to “sophisticated U.S. investors,” company documents show. One of the beneficiaries was Rep. Tom Price, a Georgia Republican poised to become secretary of the Department of Health and Human Services, which regulates pharmaceuticals.
Commentary: Big data serves patients and people in increasingly broad ways | Healthcare IT News
Big data in healthcare has been seized on by major vendors and large health systems, particularly with incentives related to population health. In what ways does this movement support patients?
An NPR/Ipsos poll shows that almost half of Americans, including Democrats, don't know the Affordable Care Act reduced the number of people without insurance.